Estimations des analystes de Wall Street pour Thermo Fisher Scientific Inc. (TMO): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-10-28 | $6.40 | ||
| 2026-07-23 | $6.03 | $5.72 | +5.4% |
| 2026-04-23 | $5.44 | $5.25 | +3.6% |
| 2026-01-29 | $6.57 | $6.45 | +1.9% |
| 2025-10-22 | $5.79 | $5.50 | +5.3% |
| 2025-07-23 | $5.36 | $5.23 | +2.5% |
| 2025-04-23 | $5.15 | $5.10 | +1.0% |
| 2025-01-30 | $6.10 | $5.94 | +2.7% |
Ratios de valorisation
| Ratio P/E | 36.71 |
| Prix / Valeur comptable | 4.81 |
| EV / EBITDA | 24.37 |
| Rendement du dividende | 0.27% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $18.27B | $20.92B | $24.36B | $25.54B | $32.22B | $39.21B | $44.91B | $42.86B | $42.88B | $44.56B |
| Coût des Ventes | $9.69B | $11.24B | $13.37B | $14.20B | $16.19B | $19.58B | $25.90B | $25.66B | $25.15B | $27.78B |
| Marge Brute | $8.58B | $9.68B | $10.99B | $11.34B | $16.03B | $19.63B | $19.01B | $17.19B | $17.73B | $16.78B |
| R&D | $754.8M | $888.0M | $967.0M | $1.00B | $1.18B | $1.41B | $1.47B | $1.34B | $1.39B | $1.40B |
| Frais Généraux | $4.87B | $5.41B | $6.03B | $6.06B | $6.95B | $7.91B | $9.02B | $8.41B | $8.68B | $7.27B |
| Charges Opérationnelles | $5.72B | $6.41B | $7.12B | $7.08B | $8.13B | $9.32B | $10.49B | $9.75B | $10.07B | $8.67B |
| Résultat Opérationnel | $2.86B | $3.27B | $3.87B | $4.26B | $7.90B | $10.32B | $8.53B | $7.45B | $7.66B | $8.11B |
| EBITDA | $4.25B | $5.05B | $6.20B | $7.02B | $10.11B | $11.97B | $11.94B | $11.20B | $11.80B | $11.47B |
| Charges d'Intérêt | $469.6M | $592.0M | $667.0M | $676.0M | $553.0M | $536.0M | $726.0M | $1.49B | $1.65B | $1.42B |
| Résultat Avant Impôts | $2.02B | $2.43B | $3.26B | $4.07B | $7.23B | $8.84B | $7.66B | $6.24B | $7.00B | $7.27B |
| Impôts | -$1.4M | $201.0M | $324.0M | $374.0M | $850.0M | $1.11B | $703.0M | $284.0M | $657.0M | $547.0M |
| Résultat Net | $2.02B | $2.23B | $2.94B | $3.70B | $6.38B | $7.72B | $6.95B | $6.00B | $6.33B | $6.74B |
| BPA | $5.12 | $5.64 | $7.31 | $9.24 | $16.10 | $19.61 | $17.73 | $15.53 | $16.58 | $17.77 |
| BPA Dilué | $5.09 | $5.59 | $7.24 | $9.17 | $15.98 | $19.46 | $17.64 | $15.45 | $16.53 | $17.74 |
| Actions en Circulation (Diluées) | $397.4M | $398.0M | $406.0M | $403.0M | $399.0M | $397.0M | $394.0M | $388.0M | $383.0M | $377.0M |
Prix
| Prix | $658.32 |
| Capitalisation | $244.6B |
| Bourse | NYSE |
| Pays | US |
Entreprises liées: A · ABT · AMGN · AZN · DHR · IQV · ISRG
Explorer le secteur: Healthcare · Medical - Diagnostics & Research
Plus de sections de TMO: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions